# NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
Canonical URL: https://biopharmsignal.com/news/NMTC/neuroone-to-report-second-quarter-fiscal-year-2025-financial-results-on-tuesday--797351db
Ticker: NMTC
Company: NeuroOne Medical Technologies
Source: NeuroOne Medical Technologies
Published: 2025-05-01 13:55 EST
## Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical...

## Article Body
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025.

Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company’s second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Second Quarter 2025 Earnings Conference Call Date: Tuesday, May 13, 2025 Time: 8:30 a.m. Eastern time U.S. Dial-In (Toll Free): 888-506-0062 International Dial-In: 973-528-0011 Participant Access Code: 655933 Webcast: 2Q25 Webcast Link

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Tuesday, May 27, 2025. To listen, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 52404. A webcast replay will also be available using the webcast link above through May 27, 2025.

About NeuroOne

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com .

IR Contact MZ Group – MZ North America NMTC@mzgroup.us
## Recent Company News
- 2025-09-08 20:05 EST — [NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025](https://biopharmsignal.com/news/NMTC/neuroone-to-participate-in-sidoti-small-cap-conference-on-september-17th-and-18t-d0cb5764) — Source: NeuroOne Medical Technologies
- 2025-08-18 12:30 EST — [NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain](https://biopharmsignal.com/news/NMTC/neuroone-receives-fda-510-k-clearance-for-onerf-trigeminal-nerve-ablation-system-b8800223) — Source: NeuroOne Medical Technologies
- 2025-08-14 11:30 EST — [NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%](https://biopharmsignal.com/news/NMTC/neuroone-reports-third-quarter-fiscal-year-2025-financial-results-revenue-increa-2aa62a86) — Source: NeuroOne Medical Technologies
- 2025-07-31 16:12 EST — [NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update](https://biopharmsignal.com/news/NMTC/neuroone-to-report-third-quarter-fiscal-year-2025-financial-results-on-thursday--da73b95a) — Source: NeuroOne Medical Technologies
- 2025-07-31 12:30 EST — [NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time](https://biopharmsignal.com/news/NMTC/neuroone-to-report-third-quarter-fiscal-year-2025-financial-results-on-thursday--4c1f9af8) — Source: NeuroOne Medical Technologies
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)